At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 586 enrolled
Drug / intervention
albiglutide + insulin glargine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared With the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating albiglutide + insulin glargine and insulin glargine + preprandial lispro insulin for Diabetes Mellitus, Type 2. Completed, enrolled 586 participants across 209 sites in 14 countries.
Detailed Summary
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesBrazil, France, Germany, Hong Kong, India, Mexico, Peru, Philippines, South Africa, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedSep 2009
Primary CompletionOct 2011
Study CompletionMay 2012
TodayJul 2026
First PostedSep 14, 2009
Enrollment StartSep 1, 2009
Primary CompletionOct 1, 2011
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.8 years ago
Interventions
albiglutide + insulin glarginebiological
albiglutide in combination with insulin glargine
insulin glargine + preprandial lispro insulindrug
insulin glargine in combination with preprandial lispro insulin